- Common sleep medication may hinder brain’s waste-clearance mechanism
- Hormonal contraceptives and breast cancer risk in BRCA1 carriers
- US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
- Eli Lilly’s Omvah gains FDA approval for treating Crohn’s disease
- Beyond body mass index, experts hone in on new definition of obesity
- Eight people die in Tanzania due to possible Marburg virus disease: WHO
- India’s Tata Group grants $57.8 million to build medical school in IT capital
- Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million
- Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion
- Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion
- Easy access to green spaces may solve screen addiction problems in kids
- Pfizer’s experimental drug improves survival rates in hard-to-treat bladder cancer
- Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million
- Vertex, China’s Zai to develop, commercialise kidney disease drug
- Pfizer’s trial antibody for type of bladder cancer meets main goal
Hormonal contraceptives and breast cancer risk in BRCA1 carriers
- January 17, 2025
US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
- January 16, 2025
Eli Lilly’s Omvah gains FDA approval for treating Crohn’s disease
- January 16, 2025
Research
Opinion
Boundaries between normal and abnormal are often thin and blurred
- by HealthQuill
- January 8, 2025
Weaving mental science into tortured art geniuses — from Rumi to Van Gogh
- by HealthQuill
- December 12, 2024